Get the Stockscreener App
13.36
0.41%
-0.05
Evolus Inc stock is traded at $13.36, with a volume of 502.33K.
It is down -0.41% in the last 24 hours and up +24.35% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$13.41
Open:
$13.35
24h Volume:
502.33K
Relative Volume:
0.70
Market Cap:
$849.14M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-12.37
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-4.40%
1M Performance:
+24.35%
6M Performance:
+3.45%
1Y Performance:
+1.56%
1-Day Range:
$13.24
$13.99
1-Week Range:
$12.84
$13.99
52-Week Range:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.37 | 849.14M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
171.83 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.55 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.555 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.69 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
122.36 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus (NASDAQ:EOLS) Trading Down 6.5%What's Next? - MarketBeat
BlackRock, Inc. Expands Stake in Evolus Inc with Strategic Acqui - GuruFocus.com
How the (EOLS) price action is used to our Advantage - Stock Traders Daily
Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News
Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat
HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN
Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat
4 Analysts Have This To Say About Evolus - Benzinga
Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia
Stifel maintains Buy on Evolus, price target steady at $25 By Investing.com - Investing.com South Africa
Evolus projects robust 2025 growth with upcoming product launches - MSN
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance - BioSpace
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why - Yahoo! Voices
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Benzinga
Evolus Shares Surge 34% on Record Q4 Revenue and FDA Approval Ex - GuruFocus.com
Evolus (NASDAQ:EOLS) Receives Buy Rating from Needham & Company LLC - MarketBeat
Evolus (NASDAQ:EOLS) Shares Gap UpHere's What Happened - MarketBeat
Evolus shares surge on strong Q4 results and upbeat 2025 outlook - MSN
Evolus announces Q4 preliminary unaudited net revenue of $79M - MSN
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Evolus Shares Rise on Jump in Revenue -January 21, 2025 at 09:28 am EST - Marketscreener.com
Evolus Shares Rise on Jump in Revenue - MarketWatch
Evolus shares surge on strong Q4 results and upbeat 2025 outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Trend Tracker for (EOLS) - Stock Traders Daily
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 (NASDAQ:EOLS) - Seeking Alpha
Evolus (NASDAQ:EOLS) Hits New 1-Year LowHere's Why - MarketBeat
Barclays PLC Buys 68,213 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Possible Bearish Signals With Evolus Insiders Disposing Stock - Simply Wall St
Evolus stock touches 52-week low at $10.23 amid market shifts - Investing.com Nigeria
Evolus (NASDAQ:EOLS) Sets New 52-Week LowHere's What Happened - MarketBeat
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Beaver Sandra | Chief Financial Officer |
Dec 23 '24 |
Sale |
10.85 |
1,586 |
17,211 |
146,916 |
| MOATAZEDI DAVID | See Remarks |
Dec 23 '24 |
Sale |
10.85 |
10,502 |
113,967 |
522,847 |
| Beaver Sandra | Chief Financial Officer |
Sep 06 '24 |
Sale |
14.98 |
3,276 |
49,074 |
148,502 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Aug 30 '24 |
Sale |
15.85 |
5,631 |
89,251 |
82,375 |
| MOATAZEDI DAVID | See Remarks |
Jun 06 '24 |
Option Exercise |
7.28 |
175,940 |
1,280,843 |
709,289 |
| MOATAZEDI DAVID | See Remarks |
Jun 05 '24 |
Option Exercise |
5.46 |
155,278 |
847,818 |
688,627 |
| MOATAZEDI DAVID | See Remarks |
Jun 06 '24 |
Sale |
12.59 |
175,940 |
2,214,486 |
533,349 |
| MOATAZEDI DAVID | See Remarks |
Jun 05 '24 |
Sale |
12.92 |
155,278 |
2,006,456 |
533,349 |
| MOATAZEDI DAVID | See Remarks |
Jun 04 '24 |
Sale |
12.73 |
140,214 |
1,784,686 |
533,349 |
| Malik Vikram | Director |
Jun 03 '24 |
Sale |
12.96 |
7,500 |
97,203 |
246,514 |
0.96%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):